RecruitingPhase 1Phase 2NCT06883526
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment
60 participants
Start Date
May 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Fully understand this study and voluntarily sign the ICF；
- Age ≥18 at ICF signing, regardless of gender；
- Histologically confirmed relapsed or refractory lymphoma.
Exclusion Criteria3
- Lymphoma with known CNS involvement；
- Severe cardiovascular/cerebrovascular diseases.
- Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Interventions
BIOLOGICALZG005 for Injection
intravenous infusion
DRUGGecacitinib Hydrochloride Tablets
Oral
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06883526
Related Trials
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT0233266817 locations
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT065103613 locations
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
NCT052943671 location